CME Information
Overview
Provider Statement
This continuing medical education activity is provided by 
Support Statement
This activity is supported by an educational grant from Genentech, Inc.
Activity Description
Crohn’s disease (CD) is a chronic, progressive, idiopathic inflammatory disorder that can affect any component of the gastrointestinal tract. Approximately 780,000 individuals in the United States have CD, with the incidence and prevalence increasing worldwide. The ongoing clinical evaluation of emerging therapies with unique mechanisms of action holds promise for a more optimal disease response. Over the past 20 years, biologic agents have redefined the management of moderate to severe CD. Agents that impact not only clinical response and remission but also mucosal healing are now of paramount interest. Available biologic therapies for CD include anti–tumor necrosis factor-α agents, an integrin inhibitor, and interleukin 12/23 inhibitors--all of which are administered either intravenously or subcutaneously. Several oral small-molecule therapies are also under investigation for the treatment of moderate to severe CD, including Janus kinase protein inhibitors. Oral agents that modulate sphingosine 1-phosphate, which guides lymphocyte circulation through secondary lymphoid organs such as the spleen and lymph nodes, are being studied as well. In this CME activity, experts summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for treating moderate to severe CD. The most recent clinical findings on the safety and efficacy of therapies targeting immunological pathways are also evaluated.
Target Audience
The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with moderate to severe Crohn’s disease.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Describe emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.
- Assess new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe Crohn’s disease.
Activity Chair
William J. Sandborn, MD
Distinguished Professor of Medicine
Chief, Division of Gastroenterology
Director, UCSD IBD Center
UC San Diego Health System
La Jolla, CA
Faculty
Jessica R. Allegretti, MD, MPH
Associate Director, Crohn’s and Colitis Center
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, March 31, 2021, to March 30, 2022.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.
Activity Chair and Faculty report the following relationship(s)
Jessica R. Allegretti, MD, MPH
Consulting Fee: Artugen, Bacainn, Finch Therapeutics, Iterative Scopes, Janssen, Morphic, Pandion, Pfizer, Salix, Servatus, Takeda
Contracted Research: Merck
William J. Sandborn, MD
Consulting Fee: AbbVie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead, Gossamer Bio, Incyte, Janssen, Kyowa Kirin, Landos, Lilly, Oppilan, Otsuka, Pfizer, Progenity, Prometheus, Reistone, Seres, Shire, Sienna Biopharmaceuticals, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance, TiGenix, Tillotts, UCB, Ventyx, Vimalan Biosciences, Vivelix
Contracted Research: AbbVie, Amgen, Atlantic Healthcare, Celgene/Receptos, Genentech, Gilead, Janssen, Lilly, Pfizer, Prometheus, Takeda
Ownership Interest: BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan, Progenity, Prometheus, Ritter, Shoreline, Ventyx, Vimalan Biosciences
Bruce E. Sands, MD, MS
Consulting Fee: Abivax, Arena Pharmaceuticals, Bacainn Therapeutics, Boston Pharmaceuticals, Calibr, Celltrion, Genentech, Gilead, GlaxoSmithKline, Index Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Kallyope, Pfizer, Prometheus, Protagonist Therapeutics, Surrozen, Takeda, Target RWE, USWM Enterprises, Viela Bio
Contracted Research: Arena Pharmaceuticals, Theravance
Reviewer reports the following relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com